World Wires · story 20443 · unverified · 1 source(s)

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites

Open in the desk

Coverage

• FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® GlobeNewswire: public companies · tier D · clear net · 2026-10-05 08:00 UTC
• FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® GlobeNewswire: public companies · tier D · clear net · 2026-10-05 08:00 UTC

What this site indexes